Epirubicin/Cyclophosphamide followed by Docetaxel as Primary Systemic Therapy in Breast Cancer
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: The aim of this study was to evaluate the activity and toxicity of EC (epirubicin/cyclophosphamide) followed by docetaxel (DTX) as primary systemic therapy in locally advanced breast cancer. We previously reported the pathological and objective responses of this study. Another follow-up period of 5 years (5-y) has passed, and the 5-y overall survival (OS) and relapse-free survival (RFS) rates have been determined. Patients and Methods: Patients of the T2-4 (＞3 cm) or N1-3 were included. Patients received E (90 mg/m2) and C (600 mg/m2) for 4 cycles followed by DTX (70 mg/m2) for 4 cycles.Results: Overall (n=46), 5-y OS was 93.2% and 5-y RFS was 72.9%. In subgroup analysis, 5-y OS and RFS were 96.4% and 70.6% in luminal, 100% and 50% in luminal-HER2, 71.4% and 57.1% in HER2, 100% and 100% in triple negative.Conclusion: This treatment provides survival benefit especially for patients with triple-negative breast cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Epirubicin/Cyclophosphamide followed by Docetaxel as Primary Systemic Therapy in Breast Cancer
- Date Crossref
- 01/01/2014
- Éditeur
- The Japanese Society of Strategies for Cancer Research and Therapy
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Tokyo Women's Medical University Adachi Medical Center pays non établi dans la noticeÉtablissement de santé
-
Tokyo Women’s Medical University Medical Center East Department of Breast Surgery pays non établi dans la noticeUniversité ou école supérieure
Tokyo Women's Medical University Adachi Medical Center et Department of Breast Surgery — Tokyo Women’s Medical University Medical Center East.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.